Growth Hormone Deficiency (GHD) - Pipeline Analysis and Market Forecasts to 2016

Summary

GlobalData, the industry analysis specialist’s new report, “Growth Hormone Deficiency (GHD) - Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global growth hormone deficiency market. The report identifies the key trends shaping and driving the global growth hormone deficiency market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global growth hormone deficiency sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The scope of the report includes:
- Annualized global growth hormone deficiency revenues data from 2001 to 2009, forecast forward for 7 years to 2016.
- Geographic markets covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.
- Analysis of the current and future market competition in the global growth hormone deficiency market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the future market associated with growth hormone deficiency.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global growth hormone deficiency market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global growth hormone deficiency market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global growth hormone deficiency market landscape? – Identify, understand and capitalize.

1 Table of contents
1 Table of contents 3
1.1 List of Tables 4
1.2 List of Figures 4
2 Growth Hormone Deficiency (GHD): Market Characterization 5
2.1 Overview 5
2.2 GHD Drugs Market Size 5
2.3 GHD Drugs Market Forecast and CAGR 6
2.4 Drivers and Barriers for the GHD Therapeutics Market 7
2.4.1 Drivers for the GHD therapeutics market 7
2.4.2 Barriers for the GHD therapeutics market 8
2.5 Opportunity and Unmet Need 8
2.6 Key Takeaway 10
3 GHD Therapeutics Market: Competitive Assessment 11
3.1 Overview 11
3.2 Strategic Competitor Assessment 11
3.3 Product Profile for the Major Products in the GHD Market 12
3.3.1 Genotropin 12
3.3.2 Humatrope 12
3.3.3 Nutropin 13
3.3.4 Saizen 14
3.3.5 Norditropin 15
3.4 Key Takeaway 16
4 Growth Hormone Deficiency Market: Pipeline Assessment 17
4.1 Overview 17
4.2 Strategic Pipeline Assessment 17
4.2.1 Technology Trends Analytic Framework 17
4.3 GHD Therapeutics – Promising Drugs under Clinical Development 19
4.4 Molecule Profile for Promising Drugs/Vaccines under Clinical Development 20
4.4.1 LB03002 (LG Life Sciences/ Biopartners) 20
4.4.2 ALTU-238 (Altus Pharmaceuticals) 20
4.4.3 ARX-201 (Ambrx/ Merck Serono) 21
4.4.4 NN8630 (Novo Nordisk A/S) 21
4.4.5 IGF-I+GH (Insulin-like Growth Factor 1 + Growth Hormone) co-administration (Ipsen) 22
4.5 GHD Therapeutics Market – Clinical Pipeline by Mechanism of Action 23
4.5.1 GHD Pipeline – Pipeline by Clinical Phases of Development 23
4.5.2 GHD Therapeutics – Phase III Clinical Pipeline 24
4.5.3 GHD Therapeutics – Phase II Clinical Pipeline 24
4.5.4 GHD Therapeutics – Phase I Clinical Pipeline 24
4.5.5 GHD Therapeutics – Preclinical Phase Pipeline 24
4.6 Key Takeaway 25
5 GHD Therapeutics Market: Implications for Future Market Competition 26
6 GHD Therapeutics Market: Future Players in the GHD Market 28
6.1 Introduction 28
6.2 LG Life Sciences, Korea 29
6.2.1 Overview 29
6.2.2 LB03002 (LG Life Sciences/Biopartners) 29
6.3 Altus Pharmaceuticals, the US 30
6.3.1 Overview 30
6.3.2 ALTU-238 30
6.4 Ambrx, Inc., the US 31
6.4.1 Overview 31
6.4.2 ARX-201 31
6.5 Novo Nordisk A/S, Denmark 32
6.5.1 Overview 32
6.5.2 NN8630 (Novo Nordisk A/S) 33
6.6 Ipsen S.A., France 33
6.6.1 Overview 33
6.6.2 IGF-I+GH (Insulin-like Growth Factor 1 + Growth Hormone) co-administration (Ipsen) 34
7 GHD Therapeutics Market: Appendix 35
7.1 Market Definitions 35
7.2 Abbreviations 35
7.3 Research Methodology 36
7.3.1 Coverage 36
7.3.2 Secondary Research 37
7.3.3 Forecasting 37
7.3.4 Primary Research 40
7.3.5 Expert Panel Validation 40
7.4 Contact Us 40
7.5 Disclaimer 40
7.6 Sources 41